Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in ...

New 3D tissue model offers a breakthrough tool for understanding and treating scleroderma and other fibrotic diseases.

Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development program from ...

April 2, 2025 Quoin Pharmaceuticals announced positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study. After six months of treatment with QRX003, significant ...

First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic ...

Puffy hands and fingers, as well as other symptoms, can precede the “warning sign” of Raynaud’s syndrome as the initial ...

Researchers from Tufts University School of Dental Medicine have developed lab-grown skin that replicates the complexity of scleroderma. Made from patient-derived cells, the 3D tissue model increases ...

Alexandra Briskey, an Arizona woman whose voice was affected by scleroderma, received a life-changing double lung transplant ...

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

For the 300,000 Americans living with the immune disease scleroderma, better treatments can't come soon enough. The rare and sometimes fatal illness stiffens and scars tissue in organs like the ...

Using skin and blood samples from scleroderma patients, the team grew lab-based skin: pinkish, pancake-like, little disks of tissue that more fully replicate how the disease develops in the body.